Advertisement

Topics

Chimeric antigen receptor T-cell therapies for lymphoma

12:58 EDT 31 Aug 2017 | Nature Publishing

Cell-based immunotherapies are showing great promise in the treatment of even the most treatment-refractory of haematological malignancies. Herein, Jennifer Brudno and James Kochenderfer review the results obtained to date with CAR-T-cell therapies for lymphoma. They also discuss what has been learned regarding the limitations of CAR-T-cell therapies and areas for improvement relating to toxicity management, the design of CAR-T-cell products, conditioning regimens, and combination therapies.

Original Article: Chimeric antigen receptor T-cell therapies for lymphoma

NEXT ARTICLE

More From BioPortfolio on "Chimeric antigen receptor T-cell therapies for lymphoma"

Quick Search
Advertisement